- German DAX retreats from zone of historical highs
- Market volatility will be limited by the US holiday
- Wall Street session today will not take place, and trading on many instruments will be shorter
General market situation:
Monday's session on European stock markets brings a slight retreat on most stock indexes. The German DAX is currently losing 0.14% on an intraday basis. At the same time, the French CAC40 is down 0.26%. The DAX remains close to its all-time highs. It is worth remembering that in view of the US banking holiday, today's session may be characterized by lower volatility than usual. There are also no significant macro data releases scheduled for the second part of the day.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
Volatility currently observed in the broad European market. Source: xStation
The German benchmark DE40 traded nearly 0.42% lower during Monday's session, but nevertheless maintained a dynamic upward trend throughout. The index broke above the key resistance level set by the 50-day EMA (blue curve on the chart) and the local peaks of the consolidation zone of the last few sessions. The dynamic breakthrough of these zones theoretically opened the way for further increases towards the historical peaks at 19,000 points. At this point, however, the index has negated the breakthrough of this zone and we are seeing a pullback. It is worth bearing in mind that the scale of the recent rebound is sizable, which may lead investors to book some of the gains. In this aspect, a relatively important support zone may be the previously mentioned 50-day EMA and 100-day EMA (purple curve on the chart). Source: xStation
News:
Bayer AG's (BAYN.DE) kidney drug Kerendia reduced the relative risk of death and other serious events associated with a form of heart failure in which pumping ability is reduced at most mildly by 16%, data from a clinical trial of 6,000 people suggest. According to an asset manager at Union Investment, this information could confirm the goal of generating $2-3 billion in annual revenue from sales of the formulation. The company will now seek approval to sell the drug. The application date has not yet been announced.
Shares of Sanofi (SAN.FR) are also up nearly 2.5%. Its oral multiple sclerosis drug, tolebrutinib, reached its milestone in a Phase 3 trial, potentially clearing the way for regulatory approval, although in two other trials, patients in earlier stages of the disease did not benefit against placebo use. A positive surprise came from success in a study of a less common form of progressive multiple sclerosis.
In the UK market, however, Rightmove (RMV.UK) is the growth leader. According to media sources, REA Group is considering a takeover bid, although no details are unknown at this point.
Other news coming out of individual companies in the DAX index. Source: Bloomberg Financial LP
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
